Beigene (BGNE) Raised to Sell at BidaskClub
Beigene (NASDAQ:BGNE) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a note issued to investors on Tuesday.
A number of other research analysts have also weighed in on BGNE. Piper Jaffray Companies set a $200.00 target price on shares of Beigene and gave the company a “buy” rating in a report on Wednesday, November 7th. Zacks Investment Research raised shares of Beigene from a “sell” rating to a “hold” rating and set a $124.00 price objective for the company in a research note on Thursday, November 8th. Maxim Group set a $170.00 price objective on shares of Beigene and gave the stock a “buy” rating in a research note on Thursday, November 15th. Cowen reaffirmed a “buy” rating on shares of Beigene in a research note on Wednesday, November 7th. Finally, Guggenheim initiated coverage on shares of Beigene in a research note on Monday, September 17th. They set a “buy” rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. Beigene currently has a consensus rating of “Buy” and a consensus price target of $172.47.
BGNE stock opened at $124.33 on Tuesday. Beigene has a fifty-two week low of $77.54 and a fifty-two week high of $220.10. The company has a quick ratio of 11.47, a current ratio of 11.57 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $6.83 billion, a P/E ratio of -55.75 and a beta of 1.76.
In other Beigene news, Director Donald W. Glazer sold 2,000 shares of Beigene stock in a transaction on Thursday, August 30th. The shares were sold at an average price of $179.00, for a total transaction of $358,000.00. Following the completion of the transaction, the director now directly owns 14,384 shares of the company’s stock, valued at $2,574,736. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Amy C. Peterson sold 40,000 shares of Beigene stock in a transaction on Monday, November 12th. The stock was sold at an average price of $120.20, for a total transaction of $4,808,000.00. Following the transaction, the chief marketing officer now directly owns 194,569 shares of the company’s stock, valued at $23,387,193.80. The disclosure for this sale can be found here. Insiders have sold 65,391 shares of company stock valued at $8,504,530 over the last ninety days. 13.30% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Northern Trust Corp acquired a new position in Beigene in the 1st quarter worth $302,000. Guggenheim Capital LLC boosted its stake in Beigene by 11.1% in the 1st quarter. Guggenheim Capital LLC now owns 5,583 shares of the company’s stock worth $938,000 after purchasing an additional 558 shares during the period. Bank of Montreal Can lifted its position in Beigene by 14.2% during the 2nd quarter. Bank of Montreal Can now owns 14,593 shares of the company’s stock worth $2,243,000 after buying an additional 1,814 shares in the last quarter. Fred Alger Management Inc. lifted its position in Beigene by 17.8% during the 2nd quarter. Fred Alger Management Inc. now owns 17,988 shares of the company’s stock worth $2,765,000 after buying an additional 2,718 shares in the last quarter. Finally, BNP Paribas Arbitrage SA lifted its position in Beigene by 365.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,367 shares of the company’s stock worth $364,000 after buying an additional 1,859 shares in the last quarter. 83.69% of the stock is owned by institutional investors.
BeiGene, Ltd. develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
See Also: Why does a company issue an IPO?
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.